We aimed to test if early, perfusion phase tau-PET imaging with [F]THK5351 might substitute for [F]FDG PET information on neurodegeneration, as has been previously shown for amyloid-tracers. A patient with cognitive impairment and positive amyloid-PET was examined by [F]THK5351 tau-PET and [F]FDG PET. The pattern of early phase of [F]THK5351 uptake was compared to [F]FDG visually and by the dice similarity coefficient. Visual inspection of axial slices and stereotactic-surface projection indicated a striking agreement between combined 0-2 min p.i. perfusion images of [F]THK5351 and standard [F]FDG 30-60 min p.i. A two-phase protocol of [F]THK5351 PET might give information on neurodegeneration and tau pathology in a single session.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159627 | PMC |
| http://dx.doi.org/10.3233/ADR-170023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Toward standardization of tau PET imaging corresponding to various tau PET tracers: a multicenter phantom study.
Ann Nucl Med
September 2023
Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, 35-2, Sakae-Cho, Itabashi-Ku, Tokyo, 173-0015, Japan.
Objective: Tau positron emission tomography (PET) imaging is a recently developed non-invasive tool that can detect the density and extension of tau neurofibrillary tangles. Tau PET tracers have been validated to harmonize and accelerate their development and implementation in clinical practice. Whereas standard protocols including injected dose, uptake time, and duration have been determined for tau PET tracers, reconstruction parameters have not been standardized.
View Article and Find Full Text PDFMicroPET Imaging Assessment of Brain Tau and Amyloid Deposition in 6 × Tg Alzheimer's Disease Model Mice.
Int J Mol Sci
May 2022
Department of Pharmacology, College of Medicine, Gachon University, Incheon 21999, Korea.
Alzheimer's disease (AD) is characterized by the deposition of extracellular amyloid plaques and intracellular accumulation of neurofibrillary tangles (NFT). Amyloid beta (Aβ) and tau imaging are widely used for diagnosing and monitoring AD in clinical settings. We evaluated the pathology of a recently developed 6 × Tg - AD (6 × Tg) mouse model by crossbreeding 5 × FAD mice with mice expressing mutant (P301L) tau protein using micro-positron emission tomography (PET) image analysis.
View Article and Find Full Text PDFCentiloid scale analysis for F-THK5351 PET imaging in Alzheimer's disease.
Phys Med
February 2021
Institute of Cyclotron and Drug Discovery Research, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Fukushima 963-8052, Japan; Department of Radiology, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, Japan.
Purpose: A standardized method for quantification is required for analyzing PET data, but such standards have not been established for tau PET imaging. The Centiloid scale has recently been proposed as a standard method for quantifying amyloid deposition on PET imaging. Therefore, the present study aimed to apply the Centiloid scale to F-THK5351 PET imaging in Alzheimer's disease (AD).
View Article and Find Full Text PDFGray matter structural networks related to F-THK5351 retention in cognitively normal older adults and Alzheimer's disease patients.
eNeurologicalSci
March 2021
Department of Radiology, National Center of Neurology and Psychiatry, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo 187-8551, Japan.
Objective: This study aimed to examine the alterations in gray matter networks related to tau retention in Alzheimer's disease (AD) patients and cognitively normal (CN) older individuals.
Methods: Eighteen amyloid-positive AD patients and 30 age- and sex-matched amyloid-negative CN controls were enrolled. All underwent 3D T1-weighted MRI, amyloid positron-emission tomography imaging (PET) with C-Pittsburgh Compound B (PiB), and tau PET with F-THK5351.
The Added Value of Tau-PET in the Assessment of Progressive Supranuclear Palsy.
Clin Nucl Med
May 2020
From the Department of Nuclear Medicine.
Progressive supranuclear palsy (PSP) is rare neurodegenerative disorder characterized by deposition of fibrillar aggregates of 4R tau-protein in neurons and glial cells. This disorder is underdiagnosed due to the overlap of the clinical syndrome with other related conditions. The clinical manifestations include cognitive impairment associated with behavioral changes, akinetic rigid syndrome, and prominent oculomotor dysfunction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!